Patent ID: 7951798

Claim:
Crystalline form I of 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]-benzodiazepine dihydrochloride, wherein the X-ray powder diffraction data and pattern are shown in Table 1 and FIG. 1 , respectively, measured using CuK α radiation: TABLE 1 Position of diffraction lines and relative intensities (>5%) Peak 2*th D(hkl) I(abs) I(rel) No. [degree] [Å] [cts] [%] 1 10.38 8.5918 1017 66.47 2 12.28 7.2072 89 5.82 3 12.59 7.0305 303 19.80 4 16.31 5.4338 108 7.06 5 17.13 5.1770 693 45.29 6 18.21 4.8707 158 10.33 7 18.40 4.8219 240 15.69 8 19.38 4.5802 264 17.25 9 20.62 4.3079 1530 100 10 21.07 4.2157 199 13.01 11 22.05 4.0320 424 27.71 12 23.50 3.7862 170 11.11 13 23.85 3.7314 432 28.24 14 24.39 3.6494 142 9.28 15 25.10 3.5474 518 33.86 16 25.88 3.4434 547 35.75 17 28.06 3.1805 309 20.20 18 30.26 2.9536 199 13.01 19 30.80 2.9028 115 7.52 20 31.05 2.8803 152 9.93 21 31.17 2.8695 163 10.65 22 32.77 2.7328 148 9.67 23 33.17 2.7009 136 8.89 24 33.31 2.6895 154 10.07.